*Annals of Oncology* **3**: 867–878, 1992.

# Index of subjects Volume 3 (1992)

*(Abstract Supplements 1 and 5 not included)*


A
acquired immune deficiency syndrome
and HD S4: 69
epidemiology in Europe 595
low-dose chemotherapy and zidovudine in related lymphomas 843
non pediatric lymphoma at Kenyatta National Hospital 323
ACTH
comparison with placebo in emesis 481
acute leukemia (see leukemia)
adhesion molecules
after lysis with LAK-cells 155
in Hodgkin's disease S4: 17
adjuvant chemotherapy
for primary breast cancer 801
in high-risk rectal cancer 197
NOVP in early HD S4: 87
trial comparing i.v. CMF to an epirubicin containing regimen in breast cancer 439
with anthracyclines in breast cancer 417
adriamycin
combined with ifosfamide in soft tissue sarcoma S2: 119
in carcinoid 635
in hyperthermic perfusion for limb sarcomas S2: 111
induction treatment in breast cancer CAF + depo buserelin 768
premenopausal women with breast cancer 849
preoperatively for osteosarcoma S2: 3
advanced cancer
a quality-of-life assessment in 565
cachexia and cancer S3: 25
prognostic role of metastatic pattern 171
adverse drug reactions
anti-emetics 677
cisplatin 719
high rate in patients treated with compassionate protocols 59
leukemia related to topoisomerase II 107
nephrotoxicity 774
ondansetron 677, 719, 773, 774
renal failure 773
thrombocytopenia 719
vascular side effects 719
age
a multifactorial prognostic variable in patients with non-Hodgkin's lymphoma 45
at menarche and menopause as risk factor for breast cancer 625
AIDS (see acquired immune deficiency syndrome)
alkylation
with frequent administration of dabis maleate 241
ALL (see leukemia)
allergic reactions
to carboplatin 239
to cisplatin and carboplatin 574
to cytotoxic drugs 605
alpha-interferon (see interferons)
AML (see leukemia)
anaplastic large cell lymphoma
and Hodgkin's disease S4: 27
anemia
chemotherapy-induced anemia in patients with primary lung cancer 819
angiofollicular hyperplasia
is interferon-α an active agent? 85
animal toxicology
studies of rhizoxin 755
anorexia
cachexia and cancer S3: 25
anthracyclines
infusional anthracyclines: Is slower better? If so, why? 591
pharmakoninetics of bolus and 48-hour infusion 651
via the oral route: Luxury or necessity? 181
anticancer drugs
antitumor activity of dabis maleate 233
antitumor activity of rhizoxin 755
emerging from a crisis in drug discovery 681
frequent alkylation with dabis maleate 241
anti-emetic(s)
advances in control of emesis S3: 47
nephrotoxic potential 774
phase I trial with clebopride malate 141
placebo vs ACTH in delayed emesis 481
serotonin antagonists 677
severe vascular adverse effects 719
severe vascular adverse effects: Reply 773
antifolate
phase II study of edatrexate in chemotherapy-naive patients with metastatic breast cancer 549
phase II study with edatrexate in patients with head and neck cancer 223
anti-ideotypic-vaccines
in Hodgkin's disease S4: 97
antigens
in experimental therapy for HD S4: 97
recognition of tumor-associated antigens by T lymphocytes 11
soluble CD8, CD25 and CD30 in HD S4: 49
antiosteolytic agents
in the management of hypercalcemia 589
pamidronate in resistant hypercalcemia 661
plicamycin vs pamidronate 619
Ara-C
in refractory ALL in children 765
argimesna
in prevention of cystitis S2: 115
astrocytoma
biology and treatment of 423
autologous bone marrow transplantation
feasibility study with carboplatin, cyclophosphamide and thiotepa 855
for Hodgkin's disease S4: 95
in germ cell tumors 780, 809
in the first remission of Hodgkin's disease S4: 91
neurological and EEG study 145
5-aza-2'-deoxycytidine
phase II in testicular cancer 399

**B**
basic science
application to hematopoiesis and treatment 269
bcl-2
in Hodgkin's disease S4: 9
biochemical modulation
double biochemical modulation of 5-fU 489
fluorouracil vs high-dose folinic acid in advanced colorectal cancer 371
sequential methotrexate and 5-FU vs. FU alone in metastatic colorectal cancer 539
biological response modifiers
activation in HD S4: 13
activation of cytokines in HD S4: 13
α-IFN alone or in combination with streptozocin and doxorubicin in patients with malignant carcinoid tumors 635
α-IFN alone or with vinblastine in metastatic renal cell cancer 301
and biology of HD 5
and hematopoietic growth factors 269
enhances immunoscintigraphy with MoAbs in melanoma 664
is active in Castlman's disease? 85
phase I in combination with s.c. IL-2 559
phase I of s.c. IL-2 and α-IFN 559
retinoids in cancer prevention and therapy 513
treatment of gliomas 423
biology
of cytokines 269
of Hodgkin's disease S4: 5
bladder tumors
recombinant tumor necrosis factor for superficial tumors 741
bleomycin
in the treatment of high-risk testicular cancer 123
bone mineralization
long-term follow-up in HD S4: 105
malignant bone resorption 257
bone resorption
malignant bone resorption: Cellular and biochemical mechanisms 257
brachytherapy
intraoperative in soft tissue sarcoma S2: 62
breast cancer
adjuvant treatment with anthracyclines 417
age and risk 625
CAF and depo-buserelin in premenopausal women 849
carboplatin, 5FU, mitoxantrone in the treatment of 545
clinical value of proteins Mr 24,000, Mr 52,000 and $DF_3$ 71
CMF vs. epirubicin-containing regimen 439
comparison of CA-549, CA 15-3 and MCA 314
extra height and risk 29
high dose progestin therapy S3: 15
hormone-related markers for risk 435
hormonal withdrawal 587
ifosfamide and S3: 21
maintenance treatment: higher versus low dose 768
meta-analysis 683
mitoxantrone and mitomycin-c as second-line treatment 165
p 53 and EGFR in 246
phase I/II study with liposome-complexed mitoxantrone 445
phase II of fosquidone 406
phase II study of oral menogaril 201
phase II study with edatrexate 549
phase II study with teniposide 377
psychological distress during adjuvant treatment 393
response after hormonal withdrawal 611
sequential receptor determination and prognosis 733
tamoxifen resistance: molecular basis 503
brequinar
phase II trial in advanced melanoma 659
bryostatin
as partial agonist of PKC 527
busulfan
with cyclophosphamide in pretransplant conditioning 145

**C**
CA 15-3
a comparison with CA 15-3 and MCA in patients with metastatic breast cancer 314
cachexia
cachexia and cancer: A clinician's view S3: 25
CAF
plus depo-buserelin in premenopausal women with metastatic breast cancer 849
cancer
cancer diagnosis and treatment 422
diagnosis disclosure in a Spanish hospital 451
fate of abstracts submitted to cancer meetings 187
nutrition and 783
retinoids in prevention and therapy 513
CAP
vs CAV in ovarian cancer 37
carboplatin
allergic reactions to 239
allergic reactions to cisplatin and 574
alone or in combination in ANLL S3: 39
and 5-FU in neoadjuvant treatment in head and neck S3: 43
and 5-FU/leucovorin in breast cancer S3: 29
and 5-FU, mitoxantrone in breast cancer 545
combined with simultaneous radiotherapy S3: 33
high-dose with cyclophosphamide and thiotepa for ABMT 855
high-dose with etoposide in testicular cancer 463
intraperitoneal application 149
optimisation of dose 291
phase II study in ovarian cancer 217
phase II study in testicular cancer 163
treatment of carcinoma of unknown origin 631
treatment of head and neck tumors S3: 11
treatment of NSCLC S3: 3
carcinogenesis
AACR/EACR first joint conference: Concepts and molecular mechanisms of multistage carcinogenesis 357
cancer and nutrition 783
carcinoid
α-IFN alone or in combination with streptozocin and doxorubicin 635
carcinoma of unknown origin
subsets responsive to chemotherapy 631
cardiotoxicity
after treatment of HD S4: 111
in patients with 5-FU 88
Castleman's disease
is interferon active? 85
cervical cancer
a preoperative single course of high-dose cisplatin and bleomycin with glutathione protection in bulky stage IB/II 117
neoadjuvant chemotherapy 97
chemoembolization
considerable side effects of 113

new techniques in advanced pelvic bone malignancies S2: 37
chemotherapy (see also adjuvant chemotherapy)
(a) combination
adriamycin, streptozotocin and IFN-α in carcinoid 635
adriamycin with ifosfamide in sarcomas S2: 119
busulfan with cyclophosphamide in conditioning 145
CAF plus depo-buserelin in breast cancer 849
CAP vs CAV in ovarian cancer 37
carboplatin and 5-FU in head and neck cancer S3: 43
carboplatin and 5-FU in breast cancer S3: 29
carboplatin, 5-FU and mitoxantrone in breast cancer 545
carboplatin, etoposide and bleomycin in testicular cancer 291
carboplatin, high-dose etoposide in testicular cancer 463
carboplatin in combination in ANLL S3: 39
carboplatin, thiotepa, cyclophosphamide in ABMT 855
cisplatin-containing regimen in granulosa cell tumor 316
cisplatin, 5-FU and leucovorin in NSCLC 727
cisplatin, ifosfamide, bleomycin in testicular cancer 123
cisplatin, ifosfamide, etoposide in testicular cancer 211
CHOP vs CNOP in lymphomas 205
CMF vs epirubicin in adjuvant breast cancer 439
epirubicin and ifosfamide in mesothelioma 237
epirubicin high-dose and cisplatin in NSCLC 864
epirubicin, ifosfamide in sarcomas S2: 119
etoposide and mitoxantrone in elderly NHLS 833
etoposide, epirubicin and cisplatin in gastric cancer 861
5-FU high-dose folinic acid 87, 371, 404, 489, S3: 29
ifosfamide alternated with epirubicin/dacarbazin in sarcomas 487
MACOP-B/VACOP-B in lymphomas 645
mitomycin in combination in NSCLC 127
mitoxantrone and mitomycin-C in breast cancer 165
NOVP in early stages HD S4: 87
PAVE in Hodgkin's disease 747
PFL in head and neck cancer 79
two weekly regimen in extensive SCLC 813
VACOP-B in lymphomas 645
vinblastine and IFN-α in renal cell cancer 301
vinblastine, cisplatin with/without mitomycin-C in NSCLC 127
with zidovudine in AIDS-related lymphomas 843
(b) single agents
adriamycin in limb sarcomas S2: 111
ARA-C in ALL 765
5-Aza-2'-deoxycitidine in testicular cancer 399
brequinar sodium in melanomas 659
bryostatin 527
carboplatin allergic reactions 239, 574
carboplatin in ANLL S3: 39
carboplatin in ovarian cancer 149, 217
carboplatin in testicular cancer 163
cisplatin: allergic reaction 574
cisplatin intraperitoneal 149
dabis maleate 233, 241
edatrexate in breast cancer 549
edatrexate in head and neck cancer 223
epirubicin in testicular cancer 577
epirubicin pharmakoninetics 651
etoposide: Oral chronic therapy S3: 63
flavone acetic acid 169, 406
fludarabine 171
5-fluorouracil 87, 88, 371, 404, 539
FUdR, oil-soluble ester 367
idarubicin in ALL 765
ifosfamide via oral route 679, 723
menogaril, oral in breast cancer 201
menogaril, oral phase I 401
metotrexate in osteosarcoma S2: 7, S2: 13, S2: 17
mithramycin in hypercalcemia 619
mitomycin-C in chemoembolization 113
mitoxantrone, complexed with liposomes 445
rhizoxin 705, 707, 755
somatostatin 409
sulofenur in metastatic renal cell cancer 83
suramin in lymphomas 571
teniposide in previously untreated breast cancer 377
6-thioguanine in NSCLC 727
(c) general
allergic reactions 239, 574
anemia with chemotherapy in NSCLC 864
biochemical modulation 489
chemoembolization with 113, S2: 37
combined modality in NSCLC S3: 3
combined with radiotherapy in early HD S4: 77
combined with radiotherapy in HD 533
complexed with liposomes 419
cross-resistance with radiotherapy 254, 273
dose escalation in HD S4: 91
dose optimization 291
for primary breast cancer 801
hypertermic application S2: 71
in high-risk rectal cancer 197
induced nausea S3: 47
induced phlebitis 311
infusional therapy 591, 651
intracavitary 771
intraperitoneal in ovarian cancer 17, 149
new drug discovery 681
maintenance treatment in breast cancer 768
pneumothorax following chemotherapy 297
present trends in osteosarcoma S2: 7
results in ovarian cancer 17
transcatheter application 367
treatment of carcinoma of unknown origin 631
treatment of gliomas 423
treatment of head and neck cancer S3: 11
treatment of NSCLC S3: 3
via the oral route 181, 679, S3: 63
weekly schedule S3: 57
with simultaneous radiotherapy in NSCLC S3: 33
CHOP
to CHOP or not to CHOP... Is this the question? 183
vs CNOP in malignant lymphomas 205
cisplatin
allergic reactions to 574
and fluorouracil and leucovorin in NSCLC 727
and ifosfamide, bleomycin in high-risk testicular cancer 123
and ifosfamide, etoposide (or vinblastine) as salvage in testicular cancer 211
and simultaneous radiotherapy in NSCLC S3: 33
and viblastine with or without mitomycin in NSCLC 127
intraperitoneal therapy in ovarian cancer 149
related emesis and ACTH 481
related emesis and clebopride 141
severe vascular events with ondansetron 719
treatment of carcinoma of unknown origin 631
treatment of head and neck cancer S3: 11
treatment of NSCLC S3: 3
treatment of ovarian cancer 17

weekly schedule S3: 57
clinical trials
another opinion 492
meta-analysis. The fashion of summing-up evidence 683
not entering patients in 103
patient treatment on a compassionate basis 59
quality-of-life assessment in a phse III trial 825
recommendations for future trials in HD S4: 101
what's the problem? 96
CLL
severe autoimmune hemolytic anemia with fludarabine 171
CNS
astrocytomas: biology and treatment 423
high incidence of relapse in ALL 839
prophylactic cranial irradiation: advantages and disadvantages S3: 51
sanctuary site relapse in testicular cancer 41
colorectal cancer
biochemical modulation of 5-FU with α-IFN and leucovorin in 489
chemoembolization for liver metastases 113
5-FU alone versus high-dose folinic acid and 5-FU in the treatment 371
5-FU vs. 5-FU + intermediate dose leucovorin in 87
isolated skull metastasis 321
methotrexate and 5-FU vs. 5-FU alone in 539
treatment of 245
combined modality
for locally extensive and advanced stage Hodgkin's disease 747
in the treatment of local-regional esophageal cancer 793
neoadjuvant PFL and concomitant radiotherapy in head and neck tumor 79
vs chemotherapy in stage III-IVB Hodgkin's disease 533
vs radiotherapy in early HD S4: 77
compliance
in quality-of-life assessment in a randomized phase III trial 825
computerized tomography
analysis of fluid distribution by 149
in staging and prognosis of SCLC 469
in the diagnosis of HD S4: 45
conference
AACR/EACR on multistage carcinogenesis 357
primary breast cancer 801
sixth world conference on lung cancer 193
consent
and randomized trials 96
the ethics of not entering patients on a randomized clinical trial 103
cross-resistance
between radiotherapy and chemotherapy 254
between vinca alkaloids and rhizoxin 755
in patients with non-small-cell carcinoma of the lung refractory to chemotherapy 273
of carboplatin in advanced ovarian carcinoma 217
cytokines
activation in HD S4: 13
activation of cytokines in HD S4: 13
α-IFN alone or in combination with streptozocin and doxorubicin in patients with malignant carcinoid tumors: A randomized trial 635
α-IFN alone or with vinblastine in metastatic renal cell cancer 301
and biology of HD 5
and hematopoietic growth factors 269
enhance immunoscintigraphy with MoAbs in melanoma 664
is active in Castleman's disease? 85
phase I in combination with s.c. IL-2 559
retinoids in cancer prevention and therapy 513
treatment of gliomas 423

**D**

dabis maleate
antitumor activity in M 5076 and its subline resistant to cyclophosphamide 233
phase I of 241
dacarbazine
and epirubicin rapidly alternated with ifosfamide in the treatment of metastatic soft tissue sarcomas 487
database
international database on Hodgkin's disease S4: 59
delayed emesis
ACTH vs. placebo in the treatment of 481
depo-buserelin
and CAF in premenopausal women 849
diagnosis
cancer diagnosis disclosure in a Spanish hospital 451
cancer diagnosis disclosure in a Spanish hospital and treatment discussion 422
of soft tissue sarcoma and immunohistochemistry S2: 51
use of staging laparotomy S4: 41
with immunoscintigraphy in HD S4: 53
diet
nutrition and cancer 783
DNA content
the prognostic value in soft tissue sarcomas S2: 89
dose escalation
coneptual problems in first remission HD S4: 91
the impact of pharmacokinetically guided dose escalation strategies in phase I clinical trials 339
dose intensification (see high dose chemotherapy)
doxorubicin (see adriamycin)
drug discovery
emerging from a crisis in drug discovery 681
expression of MDR1 and resistance in sarcomas 63

**E**

edatrexate
phase II in patients with head and neck cancer 223
phase II in patients with metastatic breast cancer 549
EEG
studies in pretransplant conditioning 145
EGFR
and p53 in recurrent breast cancer 246
elderly
non-Hodgkin's lymphoma in 379
with NHLs: A combination of mitoxantrone, etoposide and prednisone 833
embolization
evaluation of oil-soluble FUdR ester for transcatheter arterial treatment of hepatomas 367
with chemotherapy in liver metastasis 113
encephalopathy
the enigma of ifosfamide encephalopathy 679
ependymoma
biology and treatment of gliomas 423
epidemiology
nutrition and cancer: Background and rationale of the European prospective investigation into cancer and

nutrition 783
the epidemiology of AIDS and associated tumors in Europe 595
epirubicin
adjuvant therapy in breast cancer 417
and ifosfamide, dacarbazine in soft tissue sarcomas S2: 125
containing regimen vs. CMF in adjuvant treatment of breast cancer 439
high-dose in testicular cancer 577
high-dose plus cisplatin in advanced NSCLC 864
or doxorubicin with ifosfamide in advanced soft tissue sarcoma S2: 119
pharmakokinetics bolus vs. 48-h infusion 651
Epstein-Barr virus
and HD S4: 27
association with Hodgkin's disease subtypes 307
biology of HD S4: 5
erythropoietin
in patients with Hodgkin's lymphoma 172
esophageal cancer
combined-modality therapy in the treatment of 793
estrogen receptors
and response by withdrawal 587
estrogen-regulated proteins Mr 24,000, Mr 52,000 and $DF_3$ in breast cancer 71
meta-analysis in breast cancer 683
response after hormonal withdrawal 611
sequential determination and prognosis in breast cancer 733
ether lipids
as signalling inhibitors in transduction 527
ethical problems
radomized trials: Another opinion 492
randomized trials: What's the problem? 96
redressing the balance 103
etoposide
and carboplatin, bleomycin in good-risk testicular cancer 291
and high-dose carboplatin in testicular cancer 463
and mitoxantrone, prednisone in elderly NHLs 833
or vinblastine with ifosfamide, cisplatin in testicular cancer 211
oral chronic therapy S3: 63
treatment of NSCLC S3: 3
Europe
the epidemiology of AIDS 595
extragonadal germ-cell tumors
management and significance of bilateral testicular biopsies 283
extramedullary plasmacytoma
clinical behaviour and response to treatment 51

**F**

flavone acetic acid
phase II trial in patients with non-small cell lung cancer 169
fludarabine
severe autoimmune hemolytic anemia in two patients 171
fluorouracil
alone vs 5-FU/methotrexate in colorectal cancer 539
alone vs high-dose folinic acid and 5-FU in colorectal cancer 371
alone weekly vs 5-FU + folinic acid in colorectal cancer 87
cardiotoxicity 88
double modulation with IFN/leucovorin 489
with carboplatin/folinic acid in breast cancer S3: 29
with carboplatin, mitoxantrone in breast cancer 545
with high-dose folinic acid in ovarian cancer 657
with leucovorin/cisplatin in NSCLC 727
with leucovorin in hepatomas 404
folinic acid (see fluorouracil)
follicular lymphomas
a pilot study of suramin in the treatment of 571
fosquidone (see flavone acetic acid)
FUdR
evaluation of oil-soluble FUdR ester 367

**G**

gastric cancer
treatment with etoposide + epirubicin + cisplatin combination chemotherapy 861
gene expression
in hematopoietic cells 269
in single Reed Sternberg cells of Hodgkin's disease: S4: 25
tumor-associated antigens 11
germ-cell cancer (see also testicular cancer)
management of extra-gonadal germ cell cancers 283
glioma
biology and treatment of 423
glutathione
protection with cisplatin 117
gonadal dysfunction
its impact on bone mineralization S4: 105
granulosa cell tumors
treatment with cisplatin containing regimen 316
growth factors
and p53 in breast cancer 246
and signal transduction 527
application of basic science to hematopoiesis 269
molecular basis for tamoxifen resistance 503
growth hormone
and risk of breast cancer? 29

**H**

head and neck cancer
chemotherapy of S3: 11
factors influencing response to chemotherapy 553
neoadjuvant therapy S3: 43
phase II trial of edatrexate 223
phase II trials of fosquidone 406
radiotherapy and neoadjuvant PFL 79
weekly treatment with cisplatin S3: 57
hematopoiesis
application of basic science to hematopoiesis 269
hemorragic cystitis
protection by argimesna S2: 115
heparin
effective prevention of chemotherapy – induced phlebitis by low-dose 311
hepatocellular carcinoma
5-fluorouracil and leucovorin 404
treatment for patients with 336
high-dose
chemotherapy for ABMT with carboplatin, thiotepa and cyclophosphamide: feasibility 855
chemotherapy with ABMT in germ cell tumors 809
cisplatin and bleomycin with glutathione in cervical cancer 117
cisplatin with etoposide in poor-risk testicular cancer 277
epirubicin with cisplatin in NSCLC 864
or standard dose in advanced soft tissue sarcomas S2: 81
progestin therapy in breast cancer S3: 15
recommendations for future trials in HD S4: 101

tamoxifen in renal cell cancer 167
therapy in germ cell tumors 780
histopathology
histopathological classification of Hodgkin's lymphomas S4: 31
HIV-related lymphoma
epidemiology in Europe 595
HD in 92 Italian patients S4: 69
in patients at Kenyatta National Hospital 323
low-dose chemotherapy and zidovudine in 843
Hodgkin's disease
activation of cytokines in S4: 13
and Epstein-Barr virus S4: 27
association of Epstein-Barr virus genome with 307
autologous bone marrow transplantation for S4: 95
biology of S4: 5
cell adhesion molecules in S4: 17
chemotherapy vs chemotherapy plus radiotherapy for stage III-IV A & B 533
current therapeutic strategies in S4: 67
diagnostic imaging studies in S4: 45
dose escalation S4: 91
experimental therapy in S4: 97
future clinical trials S4: 101
gene expression in single Reed-Sternberg cells S4: 25
growth of Hodgkin's lymphoma derived cells S4: 21
histopathological classification of S4: 31
immunoscintigraphy in S4: 53
in 92 patients with HIV infection S4: 69
international database on S4: 59
long-term effects on pulmonary function of mantle radiotherapy 455
long-term gonadal dysfunction S4: 105
management of stage II 349
NOVP and radiotherapy for early-staged S4: 87
oncogenes in S4: 9
prognostic factors S4: 63
radiotherapy vs combined modality in early stages S4: 77
role of additional radiotherapy in advanced stages S4: 83
role of radiation therapy in advanced 499
salvage radiotherapy in recurrent disease 131
second cancer after the treatment for S4: 117
serum erythropoietin levels in patients with 172
soluble CD8, CD25 and CD30 antigens as prognostic markers S4: 49
Stanford experience with combined procarbazine, alkeran and vinblastine and radiotherapy 747
thyroid, pulmonary, and cardiac sequelae after treatment for S4: 111
treatment of children with S4: 73
use of diagnostic staging laparotomy S4: 41
hormone (see also receptors)
hormone refractory metastatic prostate cancer 331
progestin therapy in breast cancer S3: 15
prognostic factors in hormone-resistant prostatic cancer 361
response after hormonal withdrawal 611
therapeutic withdrawal 587
hyperandrogenaemia
and risk of breast cancer 435
hypercalcemia
antiosteolytic agents in the management of 589
mechanisms of..., In lymphomas 664
plicamycin vs pamidronate 619
treatment with escalating doses of pamidronate 661
hyperinsulinaemia
and risk of breast cancer 435
hypersensitivity (see allergic reactions)
hyperthermia
adriamycin in hyperthermic limb perfusion S2: 111
for the treatment of soft tissue limb sarcoma S2: 7

I
idarubicin
in refractory ALL in children 765
ifosfamide
alternated with epirubicin/dacarbazine in metastatic soft tissue sarcoma 487
and cisplatin, bleomycin in high-risk testicular cancer 123
and doxorubicin in soft tissue sarcomas S2: 119
and etoposide, cisplatin in salvage treatment for testicular cancer 211
oral formulation: clinical investigation in NSCLC 723
oral formulation: The enigma of encephalopathy 679
prevention of cystitis with argimesna S2: 115
treatment of breast cancer S3: 21
imaging techniques
in HD S4: 45
in soft tissue sarcomas S2: 55
immunohistochemistry
osteonectin in osteosarcomas S2: 33
value in the diagnosis of soft tissue sarcomas S2: 51
immunoscintigraphy
immunoscintigraphy in Hodgkin's disease S4: 53
with enhancement through α-2-β interferon 664
immunotherapy
activation of cytokines in HD S4: 13
α-IFN alone or in combination with streptozocin and doxorubicin in malignant carcinoid tumors 635
α-IFN alone or with vinblastine in metastatic renal cell cancer 301
and hematopoietic growth factors 269
angioneurotic oedema and urticaria during therapy 243
enhances immunoscintigraphy with MoAbs in melanoma 664
is active in Castleman's disease? 85
phase I in combination with s.c. IL-2 559
phase I study with α-IFN 559
prognostic factors in advanced renal cell cancer treated with 475
immunotoxins
experimental therapy in Hodgkin's disease S4: 97
infusional chemotherapy
pharmacokinetics and metabolism of epirubicin administered as i.v. bolus and 48-h infusion 651
with anthracyclines is slower better? If so, why? 591
with 5-FU, carboplatin and mitoxantrone in breast cancer 545
unsulin-like growth factor
and a higher risk of breast cancer? 29
interferon(s)
α-IFN alone or in combination with streptozocin and doxorubicin in malignant carcinoid tumor 635
α-IFN alone or with vinblastine in metastatic renal cell cancer 301
enhances immunoscintigraphy with MoAbs in melanoma 664
is active in Castleman's disease? 85
phase I in combination with s.c. IL-2 559
interleukins
activation of cytokines in HD S4: 13
and hematopoietic growth factors 269
interleukin-2
angioneurotic oedema and urticaria during therapy 243

phase I study with α-IFN 559
prognostic factors in advanced renal cell cancer treated with 475
intra-arterial chemotherapy
chemofiltration and chemoembolization in advanced pelvic bone malignancies S2: 37
chemotherapy for soft tissue sarcomas S2: 67
neo-adjuvant use in soft tissue sarcomas S2: 127
preoperative in osteosarcoma with cisplatin in pelvic S2: 3
trans catheteral in hepatomas 367
with cisplatin in pelvic osteosarcoma S2: 19
intracavitary therapy
local treatment of malignant pleural mesothelioma with cytosine-arabinoside and cisplatin 771
intraperitoneal therapy
for ovarian cancer: Analysis of fluid distribution by computerized tomography 149
in ovarian cancer 17
intravesical therapy
recombinant tumor necrosis factor for superficial bladder tumors 741

**L**

laryngeal carcinoma
neoadjuvant treatment S3: 43
steroid receptor status in 387
late effects
after treatment for Hodgkin's disease S4: 111
in patients with NHLs treated with LNH-80 regimen 639
leukemias in patients treated with inhibitors of topoisomerase II 107
secondary ALL after testicular cancer 722
topoisomerase II 107
leucovorin (see folinic acid)
leukemia
ABMT with busulfan, cyclophosphamide 145
carboplatin alone or in combination in high-risk ALL 39
high incidence of CNS relapse in ALL 839
secondary ALL after testicular cancer 722
secondary ALL to topoisomerase II inhibitors 107
sensitivity of cell lines to LAK 155
treatment of refractory ALL in children 765
Lewis Y
phase I/II study of monoclonal antibody against Lewis Y hapten in relapsed small-cell lung cancer 319
limb salvage
in local recurrence of osteosarcoma S2: 23
preoperative chemotherapy for osteosarcoma with intravenous adriamycin and intra-arterial cisplatinum S2: 3
liposomes
current state in the treatment of cancer patients 419
phaseI/II study with liposome-complexed mitoxantrone in breast cancer 445
liver
chemoembolization of liver metastases 113
transcatheter arterial treatment of hepatomas 367
treatment of hepatomas 404
long-term survival
in advanced ovarian cancer 17
in aggressive lymphoma patients treated with the LNH-80 regimen 639
in early stages HD S4: 77
in the international database for HD S4: 59
lung cancer
alternating chemotherapy for small-cell lung cancer 31
chemotherapy-induced anemia in patients with 819
extensive small-cell lung cancer. A randomized comparison of two chemotherapy programs 813
feasibility of quality-of-life assessment 825
oral etoposide in the treatment of S3: 63
Sixth world conference 193
ways of better treatment of SCLC 9
lung metastases
pneumothorax following induction chemotherapy 297
the role of salvage surgery in primary childhood osteosarcoma S2: 43
lymphangiography
in newly diagnosed Hodgkin's disease S4: 45
lymphoma
age and prognosis 45
chemotherapy with MACOP-B/VACOP-B 645
CHOP vs CNOP 205
in AIDS 595
in the elderly 379
long term outcome in aggressive, treated with LNH-80 639
low-dose chemotherapy and zidovudine in AIDS-related 843
mechanism of hypercalcemia 664
non pediatric AIDS-related at Kenyatta hospital 323
pilot study with suramin in follicular 571
prognostic factors in relapsed low-grade 227, 322
relapse in stage I of Waldeyer's ring after radiotherapy 131
staging system: A proposal 711
staging system for aggressive 675
to CHOP or not to CHOP? 183

**M**

MACOP-B
and VACOP-B in lymphomas 645
magnetic resonance
in the diagnosis of HD S4: 45
maintenance
in metastatic breast cancer 768
markers
comparison of MCA, CA549 and CA15-3 in breast cancer 314
in ovarian cancer 17
new hormone related markers in breast cancer 435
mechanism of action
carcinogenesis 357
dabis maleate 233
edatrexate 549
flavone acetic acid 169
menogaril 201
oral ifosfamide 723
pamidronate 619
retinoids 513
rhizoxin 755
sulofenur 83
suramin 571
megestrol acetate
high-dose therapy S3: 15
in cachexia S3: 25
melanoma
phase II trial of brequinar sodium 659
phase II trial of fosquidone 406
menarche
role in breast cancer risk 625
meningioma
with metastatic breast carcinoma 409
menogaril
in breast cancer, phase II study of oral 201

oral anthracyclines 181
oral, phase I study for 14 consecutive days 401
menopause
and risk of breast cancer 625
mesothelioma
local treatment with intracavitary cytosine-arabinoside and cisplatin 771
with epirubicin and ifosfamide 237
meta-analysis
international database on HD S4: 59
radiotherapy vs combined modality in early stages HD S4: 77
the fashion of summing-up 683
methotrexate
in the treatment of osteosarcoma S2: 7
in the treatment of osteosarcoma: Italian experience S2: 13
in the treatment of pelvic osteosarcoma S2: 17
sequential with 5-FU in colorectal cancer 539
mithramycin
vs pamidronate in hypercalcemia 619
mitomycin-c
and mitoxantrone in breast cancer 165
in chemoembolization of liver metastases 113
in the treatment of NSCLC 127
mitoxantrone
and etoposide, prednisone in elderly lymphomas 833
and mitomycin-c in breast cancer 165
complexed with loposomes in breast cancer 445
monoclonal antibodies
in the diagnosis of HD S4: 53
in the diagnosis of melanoma 664
phase I study of, in SCLC 319
recognition of tumor-associated antigens 11
multi-drug resistance
and crisis in drug discovery 681
in human soft itssue sarcomas 63

**N**

nausea (see also anti-emetics)
as a conditioned response 393
control of chemotherapy-induced S3: 47
treatment with serotonin antagonists 677
neoadjuvant chemotherapy
a preoperative couse in cervical cancer 117
and delayed surgery for osteosarcoma of extremities S2: 39
as combined modality in soft tissue sarcoma S2: 75
in osteosarcoma of facial bones S2: 47
in osteosarcoma: present trends S2: 7
in pelvic osteosarcoma S2: 19
intra-arterial in soft tissue sarcoma S2: 127
limb sparing in osteosarcoma S2: 23
still promising in cervical cancer 97
with adriamycin and cisplatin in osteosarcoma S2: 3
with PFL on radiotherapy in head and neck cancer 79
nephrotoxicity
and ondansetron 719, 773, 774
neurotoxicity
and dabis maleate 241
in pretransplant conditioning 145
neutrons
is there a place in sarcomas? S2: 107
new drugs
an optimistic view 699
current results with rhizoxin: The evaluation of a clinical and a basic scientist 707
signal transduction inhibitors 527
when to test in chemosensitive tumors? 102
non-Hodgkin's lymphomas (see lymphomas)
non-seminomatous cancer (see testicular neoplasms)
non-small-cell lung cancer (NSCLC) (see also lung cancer)
anemia in chemotherapy treated 819
cisplatin and carboplatin with radiotherapy S3: 33
cisplatin, 5-FU/leucovorin 727
cisplatin, vinblastine with or without mitomycin-c 127
oral ifosfamide 723
phase II study of high-dose epirubicin and cisplatin 864
phase II with fosquidone 169
radiotherapy in chemotherapy resistance 273
treatment of S3: 3
NOVP
and radiotherapy for early-staged Hodgkin's disease S4: 87
nutrition
and cancer 783

**O**

oesophageal cancer
combined modality treatment 793
oestrogen receptor (see estrogen receptors)
oligondendroglioma
treatment of 423
oncogenes
and p53 in breast cancer 246
and signal transduction 527
and tumor suppressor genes 693
application of basic science to hematopoiesis 269
for tamoxifen resistance in breast cancer 503
in Hodgkin's disease S4: 9
tumor associated antigens 11
ondansetron
and advances in the control of chemotherapy-induced nausea S3: 47
can enhance nephrotoxicity? 774
not associated with adverse events 773
renal failure after 719
serotonin antagonists 677
severe vascular adverse effects 719
thrombocytopenia after 719
oral
etoposide S3: 63
ifosfamide and encephalopathy 679
ifosfamide: Clinical investigation 723
menogaril: Phase I 401
menogaril: Phase II in breast cancer 201
osteoclast
and antiosteolytic treatment 589
and bone resorption 257
and pamidronate 619
osteonectin
in osteosarcomas S2: 33
osteosarcoma
a new cell line S2: 29
chemoembolization for S2: 37
delayed surgery for metastases S2: 39
in childhood S2: 43
limb sparing in S2: 23
localized S2: 13
of extremities S2: 39
osteonectin: A new marker? S2: 33
pelvic localization S2: 19
preoperative chemotherapy S2: 3
present trends in S2: 1

primary chemotherapy and delayed surgery S2: 39
treatment of S2: 7
ovarian carcinoma
advanced, long-term results 17
CAP v.s. CAV: A randomized study 37
carboplatin: final report of a multicentric study 217
fosquidone: A phase II trial 406
granulosa cell tumors of, treatment with cisplatin regiments 316
high-dose folinic and 5-FU 657
intraperitoneal treatment 149
treatment of 17

**P**

palliative care
in cachexia S3: 25
quality-of-life assessment in a randomized phase III study 825
quality-of-life assessment in advanced cancer research 565
pamidronate
and plicamycin in symptomatic tumor-related hypercalcemia 619
as an antiosteolytic agent 619
escalating doses in resistant tumor-induced hypercalcemia 661
paraneoplastic symptoms
treatment of paraneoplastic diarrhoea in SCLC with somatostatin 409
PAVe chemotherapy
the Stanford experience 747
pediatric tumors
primary childhood osteosarcoma: The role of salvage surgery S2: 43
treatment of refractory ALL in children 765
treatment with children with Hodgkin's disease S4: 73
pelvic osteosarcoma
chemoembolization in the treatment of S2: 37
treatment of pelvic osteosarcoma S2: 19
peripheral blood stem cell
and transplantation in Hodgkin's disease S4: 95
pharmacokinetic
impact of pharmacokinetically guided dose escalation strategies in phase I trials 339
in the treatment of osteosarcomas S2: 7
infusional anthracyclines 591
of epirubicin administered i.v. bolus and 48-h infusion 551
of oral ifosfamide 679
optimization of carboplatin dose in combination with etoposide, bleomycin 291
pharyngeal cancer
neoadjuvant combination of carboplatin and 5-FU S3: 43
phase I
clebopride malate, a new antiemetic drug 141
dabis maleate, with frequent administration 241
liposome-complexed mitoxantrone 445
monoclonal antibody Lewis Y hapten in SCLC 319
oral menogaril administered daily for 14 days 401
pharmacologically guided escalation 339
phase II
5-AZA-2'-deoxycitidine (NSC 127716) in testicular cancer 399
brequinar sodium in advanced melanoma 659
carboplatin in ovarian cancer 217
carboplatin in previously untreated testicular cancer 165
edatrexate in breast cancer 549
edatrexate in head and neck cancer 223
fosquidone in various tumors 406
high-dose progestins in breast cancer S3: 15
high-dose tamoxifen in renal cell cancer 167
liposome-complexed mitoxantrone in breast cancer 445
monoclonal antibody Lewis Y hapten in SCLC 319
oral ifosfamide in lung cancer 723
oral menogaril in breast cancer 201
solufenur (LY 186641) in renal cell cancer 83
suramin in follicular lymphomas 571
teniposide in previously untreated breast cancer 377
with epirubicin and ifosfamide in mesothelioma 237
phlebitis
effective prevention of chemotherapy – induced phlebitis 311
plasmacytoma
extramedullary, clinical course 51
platinum (see cisplatin, carboplatin)
plicamycin
and pamidronate in symptomatic tumor-related hypercalcemia 619
pneumothorax
following induction chemotherapy in patients with lung metastases 297
postoperative radiation therapy
for adult soft tissue sarcomas S2: 103
in the treatment of soft tissue sarcomas of extremities S2: 93
preoperative chemotherapy (see also neoadjuvant chemotherapy)
and delayed surgery in osteosarcoma S2: 39
for osteosarcoma with i.v. adriamycin and intra-arterial cisplatin S2: 3
limb sparing in osteosarcoma S2: 23
treatment of localized osteosarcoma of extremities S2: 13
preoperative radiation therapy
in the treatment of high-risk rectal cancer 197
in the treatment of soft tissue sarcomas of extremities S2: 93
prevention
of cancer and nutrition 783
of chemotherapy induced phlebitis 311
progestins
high-dose therapy for metastatic breast cancer S3: 15
prognostic factors
abdominal CT in SCLC 469
age as multifactorial variable in lymphomas 45
carcinoma of unknown origin: Subset responding to chemotherapy 631
in advanced ovarian cancer 17
in advanced ovarian cancer treated with carboplatin 217
in breast cancer 683
in colorectal cancer 171
in elderly lymphomas 379
in head and neck cancer 553
in high-volume testicular cancer 256
in Hodgkin's disease S4: 63
in hormone-resistant prostatic cancer 361
in low grade lymphomas 322, 553
in primary breast cancer 801
in the international database for Hodgkin's disease S4: 59
osteonectin in osteosarcoma S2: 33
renal cell cancer treated with interleukin-2 475
sequential estrogen receptor determination 773
soluble CD8, CD25 and CD30 in Hodgkin's disease S4: 49
prophylactic cranial irradiation
advantages and disadvantages S3: 51
prostate cancer
hormone refractory metastatic prostate cancer 331
prognostic factors in hormone-resistant patients 361
psychological distress

during adjuvant chemotherapy as a conditioned response 393
publication
the fate of abstracts 187
pulmonary complications
after treatment for Hodgkin's disease S4: 111
long-term effects of mantle radiotherapy 455

**Q**
quality-of-life
assessment in a phase III study 825
in aggressive lymphoma patients 639
therapy impact questionnaire for assessment 565

**R**
radiological studies
in patients with Hodgkin's disease S4: 45
radiotherapy
additional radiotherapy in advanced HD S4: 83
antitumor activity in NSCLC resistant to chemotherapy 273
combined modality in NSCLC S3: 3
combined modality in rectal cancer 197
combined with PFL as neoadjuvant in head and neck cancer 79
cross-resistance with chemotherapy 254
for treatment of gliomas 423
in combination with surgery for soft tissue sarcomas of the extremities S2: 97
in stage I lymphoma of Waldeyer's ring 137
long term results in Hodgkin's disease S4: 59
postoperative radiation therapy for adult soft tissue sarcomas S2: 103
role in advanced Hodgkin's disease 499
salvage treatment in Hodgkin's disease 131
vs combined modality in early HD S4: 77
with carboplatin-5-FU in head and neck cancer S3: 43
with chemotherapy vs chemotherapy alone in stage III-IV Hodgkin's disease 533
with cisplatin and carboplatin in NSCLC S3: 33
with neutrons in osteosarcomas and soft-tissue sarcomas S2: 107
with NOVP in early HD S4: 87
with PAVe in HD 747
randomized trial
another opinion 492
best treatment for colorectal cancer and confirmatory trials 245, 439
not entering patients in 103
what's the problem? 96
receptors
and molecular mechanism of carcinogenesis 357
and signal transduction 527
and tumour suppressor genes 693
meta-analysis of steroid receptors 683
nuclear receptors in Hodgkin's disease S4: 9
sequential determination of estrogen receptors 733
steroid receptors in malignant and non-malignant larynx 387
rectal cancer
combined modality adjuvant treatment 197
Reed-Sternberg cell
biology of Hodgkin's disease S4: 5
gene expression in single Reed-Steinberg cells S4: 25
renal cell cancer
α-2a interferon with or without vinblastine 301
high dose tamoxifen: A phase II study 167
phase II study with sulofenur 83
prognostic factors in patients treated with interleukin-2 475
renal failure (see nephrotoxicity)
retinoids
in cancer prevention and therapy 513
rhizoxin
current results: The evaluation of a clinical and a basic scientist 707
preclinical antitumour activity and animal toxicology studies 755
ricin-A chain
experimental therapy in Hodgkin's disease S4: 97
risk factors
age at menarche and at menopause for breast cancer 625
and dose escalation in HD S4: 91
for adult soft tissue sarcomas S2: 85
height for breast cancer 29
new hormone-related markers in breast cancer 435
second cancer in HD S4: 91
therapy related leukemias II 107

**S**
salvage
radiotherapy in recurrent Hodgkin's disease 131
surgery in childhood osteosarcoma S2: 43
therapy for germ cell tumours 211
therapy with high-dose carboplatin for testicular cancer 463
sanctuary site
relapse in chemotherapy-treated testicular cancer 41
sarcomas (see osteosarcoma, soft tissue sarcoma)
second cancer
after the treatment for Hodgkin's disease S4: 117
therapy related leukemias in patients treated with inhibitors of topoisomerase II 107
secondary ALL following treatment for testicular cancer 722
serum markers (see markers)
signal transduction
inhibitors as novel anticancer drugs: Where are we? 527
small-cell lung cancer
a randomized comparison of two chemotherapy programs with early crossover 813
alternating chemotherapy: A twelve-week schedule of six drugs 31
phase I/II study of monoclonal antibody against Lewis Y hapten in relapsed cases 319
prophylactic cranial irradiation: Advantages and disadvantages S3: 51
role of abdominal computerized tomography on staging 469
somatostatin in the treatment of paraneoplastic diarrhoea 409
ways to a better treatment 9
soft tissue sarcomas
adriamycin in hyperthermic perfusion for advanced limb sarcomas S2: 111
chemotherapy in the multidisciplinary approach S2: 75
doxorubicin (or epidoxorubicin) combined with ifosfamide S2: 119
epirubicin plus ifosfamide and decarbazine (EID) in advanced cases S2: 125
experience with intraoperative brachytherapy S2: 63
hyperthermic antiblastic perfusion S2: 71
imaging: An integrated approach S2: 55
in adults: Biopsy yes or no? S2: 57
intra-arterial induction chemotherapy S2: 67
neoadjuvant intra-arterial chemotherapy S2: 127
neutrons therapy with high LET S2: 107
of the extremities: surgical approach S2: 59
postoperative radiation therapy S2: 103

present trends S2: 1
radiation therapy and conservative surgery of the extremities, torso and head and neck S2: 97
risk factors in northern Italy S2: 85
standard and high dose chemotherapy S2: 81
surgery and radiation therapy in the treatment of extremities S2: 93
the prognostic value of DNA content S2: 89
the value of immunohistochemistry in the diagnosis S2: 51
somatomedins
and higher risk of breast cancer 29
somatostatin
in the treatment of paraneopalastic diarrhoea in patients with small-cell lung cancer 409
Spain
cancer diagnosis disclosure in a Spanish hospital 422, 451
splenectomy
controversies in the use of diagnostic staging laparotomy and splenectomy in the management of Hodgkin's disease S4: 41
staging
a proposal for a simple staging system 711
diagnostic studies in Hodgkin's disease S4: 45
immunoscintigraphy with iodine labeled monoclonal antibodies S4: 53
impact of abdominal-computerized tomography in staging of SCLC 469
splenectomy in S4: 41
staging system for aggressive NHLs 675
subgroup analysis
international database on Hodgkin's disease S4: 59
meta-analysis. The fashion of summing-up evidence. Part II. Interpretations and uses 683
sulofenur
phase II study in measurable metastatic renal cancer 83
suppressor genes
and tumours 693
suramin
a pilot study in the treatment of progressive refractory follicular lymphomas 571
surgery
conservative with radiotherapy in sarcomas S2: 97
delayed after chemotherapy osteosarcomas S2: 39
in gliomas 423
in ovarian cancer 17
in soft tissue sarcomas S2: 59
in the treatment of localized osteosarcomas of extremities S2: 13
limb sparing versus amputation S2: 23

T
T lymphocytes
recognition of tumor-associated antigens by T lymphocytes: From basic concepts to new approaches 11
tamoxifen
adjuvant therapy of primary breast cancer 801
and breast cancer 683
high-dose in renal cell cancer 167
molecular basis for resistance 503
response after withdrawal in advanced breast cancer 611
teniposide
in advanced breast cancer. A phase II trial in patients with no prior chemotherapy 377
in low-dose chemotherapy and zidovudine in 37 patients with poor-prognosis AIDS-related-NHLs 843
testicular biopsies
in the management of extragonadal germ-cell tumours 283
testicular neoplasms
5-AZA-2′-deoxycytidine (NSC 127716), phase II trial 399
high-dose carboplatin and etoposide in salvage treatment 463
high-dose chemotherapy supported by ABMT 809
high-dose epirubicin in refractory 577
high-dose therapy: When, what, and how 780
modified cisplatin, etoposide and ifosfamide as salvage therapy 211
optimization of carboplatin dose in combination with etoposide, bleomycin 291
phase II testing 102
sanctuary site relapse 41
secondary ALL following treatment for 722
single agent activity of carboplatin in previously untreated 163
treatment of high-volume cases 256
treatment of poor-risk with high-dose cisplatin 277
when to test new drugs 102
6-thioguanine
for advanced non-small cell lung cancer 727
thiotepa
combined with carboplatin, cyclophosphamide in high-dose regimen for ABMT 855
thrombocytopenia
following emetogenic chemotherapy and ondansetron 719
side effects of chemoembolization 113
thyroid dysfunction
after treatment for Hodgkin's disease S4: 111
topoisomerase II inhibitors
therapy-related acute myeloid leukemia secondary to inhibitors of topoisomerase II 107
tubulin binder
preclinical antitumour activity and animal toxicology studies of rhizoxin 755
tumor antigen
biology of Hodgkin's disease S4: 5
gene expression in a single Reed-Sternberg cell S4: 25
in hematopoietic diseases 269
oncogenes in Hodgkin's disease S4: 9
recognition of tumour-associated antigens by T lymphocytes 11
soluble CD8, CD25, CD30 antigens in Hodgkin's disease S4: 49
tumour markers (see markers)
tumour necrosis factor
for superficial bladder tumours 741
tumour suppressor genes
tumour suppressor genes 693
tyrosine kinase inhibitors
and signal transduction 527

V
VACOP-B
and MACOP-B in intermediate- and high-grade lymphomas 645
vascular side effects
with thrombocytopenia and renal failure following emetogenic chemotherapy and ondansetron 719 and reply 773
vinblastine
and cisplatin with/without mitomycin in advanced NSCLC 127
in salvage treatment for male germ-cell tumours 211
with α-interferon in advanced renal cell cancer 301
VP16 (see etoposide)

**W**
Waldeyer's ring
stage I malignant lymphoma: Frequent relapse after radiation therapy 137
weekly schedule
alternating chemotherapy for small-cell lung cancer 31
in recurrent and metastatic head and neck cancer S3: 57
withdrawal
a therapeutic withdrawal can make a strategic advance 587
response after withdrawal of tamoxifen and progestogens in advanced breast cancer 611

**Z**
zidovudine
combined low-dose chemotherapy and zidovudine in 37 patients with poor-prognosis AIDS-related non-Hodgkin's lymphoma 843

*Annals of Oncology* **3**: 879–884, 1992.

# Index of authors Volume 3 (1992)

(*Abstract Supplements 1 and 5 not included*)


**A**
Aamdal S 774
Achtnicht U 301
Ahlström H 635
Aisner J S3: 3
Aitini E 771
Aitken SE 201, 401
Akdas A 577
Alba E 31
Albertazzi L 809
Alberto P 825
Alevizakos N 316
Alm G 635
Almeida MJ 664
Alonso JD 861
Alonso L 31
Alvegård ThA S2: 7
Amadori S 765
Ammendolia I S2: 93
Andersen J 71
Anderson H 611
Andreola S S2: 67
Ang PT 747
Ansell SM 45, 404
Antognoni P S2: 103
Anton A 861
Aranda E 861
Arena MG 741
Arienti F 155
Armand JP 223
Armen T S2: 3
Armitage JO 675, S4: 95
Arnott S 349
Ashley S 131
Astone A 171
Athanassiou AE 316
Atzpodien J 475
Avella M S2: 39
Aversa SML 833
Ayala A S2: 3
Azzarelli A S2: 43, S2: 67, S2: 125

**B**
Baars JW 243, 855
Baba Y 367
Babini L S2: 93
Bacchi M 371, 481
Bacci G S2: 13, S2: 23, S2: 39
Bachmann I 311
Bacoyiannis C 127
Baer HU 113
Bafaloukos D 631
Bai M 85
Baillet F S3: 43
Bais E 463
Bakker PJM 314
Balaña C 861
Baldini N S2: 29
Ballesteros P 31
Balzarini L S2: 55
Band PR S3: 57
Bandini N 481
Banis K 553
Barasti P S2: 47
Barbieri E S2: 93
Barone C 171
Bartolucci R 371
Barzacchi MC 559
Bassetto MA 809
Bastion Y 171, 639
Bauer HW 301
Beer M 127, 553, 631
Beerblock K 657
Behles C S4: 105
Belani CP S3: 3
Bella M 481
Belon J 31
Belsanti V 371
Benjamin RS S2: 3, S2: 81
Bennamoun M 657
Berger DP 755
Bernhard J 825
Bernhards J S4: 31
Bertelsen K 217
Bertola G 843, S2: 97, S4: 69
Bezares R 533
Biagini R S2: 13
Bianchi C 237
Bianco A 833
Bignami P S2: 67, S2: 125
Biran H 297
Bischoff H 723
Blake P 574
Blanc M 639
Bleiberg H 141
Blumgart L 113
Blythman H 319
Boas J 377
Boiocchi M 63, 307
Bokemeyer C 487, 772
Bollag W 513
Bonadonna G 417, S2: 125, S3: 1, S4: 111
Boni C 371
Bonichon F 439
Bonjour J-Ph 589
Boon T 11
Borin L 155
Borner M 113
Bosq J S4: 53
Bosse A S2: 33
Boswell W 149
Botti C S2: 71
Bovbjerg DH 393
Boz G S2: 97
Brada M 131
Brady G S4: 25
Brämswig JH S4: 73
Bramwell V S2: 75
Brandes A S3: 29
Breton JJ 31
Briassoulis E 85, 631
Briccoli A S2: 39
Brincker H 379
Brousset P S4: 27
Brunetto AL 664
Brunner K 113, 825
Bruzzi P 625
Bryon PA 171
Buckman R 201
Buesa J S2: 75
Bui NB 651
Burger W 404
Bussaka H 367
Busutti L 864

**C**
Cabanillas F 183, 227, 711, S4: 87
Calabresi F 371, 741
Camp..nacci D S2: 23
Campanacci M S2: 59
Campora E 165
Camps C 861
Cancrini A 741
Canellos GP S4: 67
Canetta R 217
Cantwell BMJ 239, 246
Cappelaere P 223
Carbone A 307, 843, S2: 51, S2: 97, S4: 69
Carde P S4: 53, S4: 77
Carlini S S2: 71
Carlson R 659
Carrasco CH S2: 3
Carrato A 861
Casadei R S2: 13, S2: 39
Casadio M 864
Casaldi V S2: 71
Casali P S2: 67, S2: 125
Cascinu S 489
Casper J 167
Cassano A 171
Castellino RA S4: 45
Castiglione M 113, 733
Castle WM 773
Catalano G 489
Cavaliere F S2: 71
Cavaliere R S2: 71
Cavalli F 8, 96, 406, 733, 825
Cavazzini G 771
Ceglia E S2: 55

Cerati M S2: 103
Cerizza L S2: 103
Cerny T 679
Cerottini J-C 11
Cervantes A 861
Cervantes G 205
Cetto GL 809
Chariot P 813
Chauvel P S2: 107
Chauvergne J 439
Chawla SP S2: 3
Chiarion-Sileni V 51, 833
Childs A 719, 773
Childs WJ 291
Chow LWC 409
Christensen BE 379
Chun HG 59
Cionini L S2: 63
Clagett-Carr K 59
Clauser L S2: 47
Clavel M 223, 399, 406
Clendeninn NJ 79
Coates AS 103, 683, 719, 773
Cocconi G 481
Cognetti F 223
Coiffier B 171, 322, 639
Coleman CN S4: 83
Collier MA 79
Collins J 733
Comis RL S3: 63
Connors JM S3: 57
Contu A 833
Cooper B 727
Cooper MR 571
Corneo G 155
Corrado C 205, 533
Corsa P S2: 93
Cossman J S4: 9, S4: 25
Costa A 533
Covizzi M 87
Cowell JK 693
Cox K 719, 773
Cricca A 87
Cruz Hernández JJ 861
Cruz JM S3: 15
Cuesta C 321
Cunningham K 773
Curioni C S2: 47
Curtin J 149

**D**

D'Agnano D 741
d'Amore F 379
D'Ardenne J 349
D'Incalci M 233
da Costa L S4: 53
Da Pian PP S2: 111
Daemen T 419
Dahmen E S4: 105
Dallaire B 659
Damstrup L 71
Daniels M 451
Daniilidis J 553
Dardanoni G 625
Daugaard G 277, 283
Davies BR 59
Dawes PJDK 246
Dazzi C S2: 19, S2: 37
de Bellefeuille C 187
de Boer M 241
de Cremoux H 813
de Cristofaro R S2: 13
de Graeff A 549
de Gramont A 657
de Mulder PHM 223
de Valeriola D 181
de Vries EGE 419
de Wit R 314
De Carli P 741
De Conno F 565
De Paoli A S2: 97
De Pascale A S2: 115
De Re V 307
Dearnaley DP 361
Decarli A 625
Delsol G S4: 27
Demuynck B 657
Denton CP 574
Depondt J S3: 43
Devizzi L S2: 125
Dgani R 297
Di Costanzo F 245, 371
Di Filippo F S2: 71
Di Re F 117
Diaz Maqueo JC 205
Díaz-Rubio E 861
Diedrich H 167
Diehl V 172, S4: 1, S4: 13, S4: 21, S4: 49, S4: 53, S4: 83, S4: 97, S4: 101, S4: 105
Dilhuydy J-M 439
Dixon DO 227
Dodwell DJ 257, 611, 664
Dolcetti R 307
Dombernowsky P 377
Dominguez S 861
Dommann C 645
Dorta J 861
Dowsett M 503
Dreef-van der Meulen HC 755
Drings P 723
Dubbelman R 463
Dubreuil C S3: 43
Dullemond-Westland A 549
Dumontet C 171, 639
Durand M 439

**E**

Earhart R 401
Eeles R 131
Eerenberg-Belmer AJM 243
Eguchi K 819
Einhorn S 635
Eisenhauer EA 83, 201
Elomaa I S2: 7
Emiliani E S2: 19
Endrizzi L 833
Engelholm SA 377
Engert A S4: 1, S4, 21, S4: 97
Enneking WF S2: 33
Erazo A 205
Errante D 843, S2: 115, S4: 69
Eskilsson J 455
Espinouse 171
Estapé J 451
Estapé T 451
Evers C 539

**F**

Fabbri N S2: 13
Falkson CI 768, 849
Falkson G 45, 336, 404, 409, 768, 849
Falkson HC 849
Farris A 87
Fattori PP 771
Faustini M 211
Favaretto A 51
Favre S 825
Fedeli A 489
Feller AC S4: 13
Felman P 639
Felsenberg D S4: 105
Fernández I 533
Fernández Martos C 861
Ferrari S S2: 39
Fetherstonhaugh EM S3: 57
Ffrench M 639
Fiebig HH 755
Filippeschi S 233
Fiorentini G S2: 19, S2: 37
Fiorentino MV 51, 833, S3: 29
Fischer JR 723
Fischer R S4: 31
Fischer RI S4: 83
Fissi S S2: 67
Fodstad Ø 755
Foladore S 237, S2: 115
Fonatsch C 772, S4: 21
Fong CM 409
Fonseca E 861
Fontanelli R 117
Forastiere AA S3: 11
Forman AD 423
Fornasiero A 51
Forsyth C 719, 773
Fortner C 59
Fosså SD 301, 361, 399, 577
Fossati Bellani F S2: 43
Foster BJ 59
Fountzilas G 553, 631
Fox BW 707
Fraile G 321
Franceschi S 595, 625, S2: 85
Franks CR 475
Frelin C 88
Freschi A S2: 115
Freund M 167, 772
Frezza G S2: 93
Frustaci S 63, S2: 97, S2: 115
Fuller L S4: 87
Fumo G S2: 97

**G**

Gad J 361
Gad-El-Mawla N S3: 21

Gamba A 565
Gambacorti-Passerini C 155
Gandara DR S3: 47
Ganesan TS 349
Ganz PA 825
Garavello M S2: 103
Garbuglia A S2: 67
Garcia I 533
Garcia Vela EL 205
Gardin G 165
Garinei R S2: 71
Gaspard MH 88
Gasparini G S2: 47
Gasparini M S2: 43
Gastaldi R 843, S4: 69
Gause A S4: 49
Gebbers JO 645
Gehanno P S3: 43
Gelber RD 683, 733, 801
Gelman RS 768
Gelmon K S3: 57
Gennari L S2: 67
Georgii A S4: 31, S4: 35
Gherlinzoni F 63, S2: 23, S2: 39, S2: 97
Giannarelli D S2: 71
Gianni L 211
Giona F 765
Gisselbrecht C 843
Giudici S 165
Glaus A 825
Glick JH 768, 801
Gloghini A S2: 51
Goldhirsch A 683, 733, 801
Goldie JH S3: 57
Goldman MD 79
Goldstone AH S4: 91
Gonzalez FG 545
González R 861
Gore M 574
Görg C S3: 33
Görg K S3: 33
Graham MA 339
Gralla RJ 677
Grandér D 635
Grandi G 237
Grau JJ 451
Graziani G S2: 19
Green MR 727
Grieco A 171
Grillo-Lopez A 659
Grygiel JJ 719, 773
Guaraldi M 87, 864
Guerrier R S3: 43
Günzel K 123
Gustavsson A 455
Gyves J 659

**H**
Hack CE 243
Hackenbruch E S3: 33
Hagemeister FB 227, 711, S4: 87
Hamilton JM 245
Hamilton-Dutoit S S4: 27
Hansen HH 9, 469
Hansmann ML S4: 9
Haraf DJ 79
Harris A 217
Harris J 768
Harstrick A 487
Hasenclever D S4: 49, S4: 101
Havemann K S3: 33
Hayes DF 71
Hayungs J 123
Hellman K 217
Hendrick AM 239
Hendriks HR 233, 755
Hennessy C 246
Henrar REC 755
Henry-Amar M S4: 59, S4: 63, S4: 117
Hepperle B S4: 5
Herbst H S4: 27
Hernández E 451
Herndon JE II 727
Herranz P 545
Herrmann R 539
Hidalgo OF 545
Hiersche A 172
Hirsch FR 469
Ho KH 409
Hoek FJ 314
Höffken K 123
Holdener EE 301, 513
Honegger HP 645
Hoppe RT 747
Hörnig-Franz I S4: 73
Horning SJ 747
Horwich A 131, 291
Hoth DF 59
Howell A 611
Hübner K S4: 31
Hürny C 825

**I**
Iannetti P 145
Iida K 137
Ingemann Jensen L 469
Innocente R S2: 97
Iori AP 765
Israels SP 463

**J**
Jacobsen PB 393
James PPB 41
Janssens N 217
Janus TJ 423
Janzek E 319
Jarque I S3: 39
Jarrett RF S4: 27
Jeffers S 149
Jensen F 469
Jimeno J 861
Johnston SRD 503
Jones DB S4: 9
Jordan VC 587
Joshua DE 719, 773
Joss RA 193, 645, 825
Jücker M S4: 13
Judson IR 406
Jung W S4: 49

**K**
Kakolyris S 127
Kaleta J S4: 5
Kanarek BB 773
Kapp U S4: 21
Karabelis A 127
Karato A 819
Karvounis N 127
Kath R 123
Kaye SB 169, 399, 406, 577, 707
Keizer J S2: 75
Kelsen D 793
Kerbrat P S2: 75
Keren-Rosenberg S 409
Khorana SM 227
Kirchner H 475
Kirkpatrick A 223
Kiser J 825
Kjorstad K 217
Kleeberg U 539
Klein S S4: 13
Klouvas G 85
Knowling MA S3: 57
Knuth A 539
Kohler D 571
Köhne-Wömpner CH 487
Kojima A 819
Kónya A S2: 127
Korsten FW 539
Kosmidis P 127, 553, 631
Kozloff MF 79
Kreuser E-D S4: 105
Krommer CF 37
Kroner T 645
Krulik M 657
Kufe DW 71
Kunikane H 819
Küpfer A 679
Kyritsis AP 423

**L**
La Rocca RV 571
La Vecchia C 625
Lacroix H 319
Landberg T 455
Landuzzi L S2: 29
Lanng Nielsen J 379
Lari S S2: 39
Larusdottir H 455
Lathan B S4: 101
Law M 361
Le Chevalier T 813
Lefebvre JL 223
Lennard TWJ 246
Leo G 387
Leonard RCF 322
LePoidevin E 149
Levin VA 423
Leyland-Jones B 59
Lindtner J 733
Lips S 141
Lise M S2: 111
Lister TA 349, S4: 83
Lluesma Goñalons M 205
Lo Re G S2: 115

Lobo Sanahuja F 533
Löchner S 723
Löffler M S4: 63, S4: 101
Loibner H 319
López F S3: 39
Louvet C 657
Ludwig EB 664
Lumbroso JD S4: 53
Luzi Fedeli S 489
Lynch W 659
Lyss AP 727

**M**
Macfarlane D 59
Macheng I 861
MacLennan K S4: 63
Madon G S2: 13
Magnasco H 205, 533
Magri MD 237
Magrini SM S4: 77
Mak TW S4: 25
Mandelli F 765, 843
Mandjes I 855
Manegold C 723
Manil L S4: 53
Manne SL 393
Mañé JM 451
Mapelli S S2: 43
Marangolo M 809, S2: 13, S2: 19
Maraveyas A 631
Mariani GL 559
Maroun JA 401
Marroni BJ 664
Marsault R 88
Marsigliante S 387
Martin A 217
Martin M S3: 43
Martin RG S2: 3
Martín G S3: 39
Martinelli G 301
Martinez-San-Millán J 321
Martínez JA S3: 39
Martoni A 87, 864
Marzano S S2: 63
Marzola M 371
Mason-Coughlin K 727
Massuti B 861
Mauch P S4: 41, S4: 59, S4: 63, S4: 77
Maurer R 645
Mauriac L 439
McEvilly J-M 79
McLaughlin P 227, 711, S4: 87
McMillan AK S4: 91
McNeil E 719, 773
Mead GM 41, 839
Meerwaldt JH S4: 83
Melanotte PL S2: 111
Meloni G 145, 765
Mencaglia E 565
Menestrina F 307
Mercuri M S2: 13
Merlini L 165
Mertelsmann R 269
Mertens W 83
Merz H S4: 13
Metzger U 825
Michiara M 481
Mick R 79
Middeke H 539
Mielcarek M S4: 105
Miglietta L 165
Miglio L 559
Milano G 88
Millward M 246
Milone G 205
Miniero R 765
Mirimanoff RO 254
Moleti ML 765
Molteni M S2: 103
Monfardini S 169, 237, 399, 595, 843, S2: 115, S4: 69
Monici L 481
Monnet I 813
Montero C 533
Monti C S2: 39
Moore M 659
Moran WJ 79
Morant R 319
Morassut S S2: 97
Morita M 273
Morrison CA 187
Morrow CP 149
Moter A 172
Mouridsen HT S2: 75
Muggia FM 149, 492
Mulder NH 419
Murray JA S2: 3
Muss HB S3: 15
Musumeci R S2: 55
Myers CE 571
Mylonakis N 127

**N**
N'Koua Mbon JB 141
Naso C 165
Natale R 659
Negri E 625
Negrier S 475
Neijt JP 17
Neri S S2: 93
Newlands ES 163
Newling DWW 361
Nicholls EJ 291
Nichols J 131
Nicolai N 211
Nicotra M 237
Niederle N 123
Nielsen D 377
Nitti D S2: 111
Norris B 201
Nyongo AO 323

**O**
O'Brien MER 574, 605
O'Dwyer PJ 59
O'Reilly SM 163
Öberg K 635
Oberling F 301
Oguni T 367
Ohe Y 819
Ohmatsu H 819
Okamoto H 819
Oksenhendler E 843
Olmeo N 833
Olmi P S2: 63
Orazi A 155
Oskam R 475
Osoba D S3: 57
Østerlind K 9, 469
Othieno-Abinya NA 323
Otto U 301
Oza A 349

**P**
Paaske Hansen O 377
Paccagnella A 51
Paietta E S4: 17
Palau J S3: 39
Pallesen G S4: 27
Palli D 625
Palmer PA 475
Palombo H 451
Palumbo R S2: 119
Pampallona S 645
Panizzoni GA S2: 47
Panje WR 79
Pannuti F 87, 864
Pansadoro V 741
Panzer JM 141
Paolucci G S2: 13
Papadopoulos NEJ S2: 3
Pape H S2: 89
Paredes G 31
Parmentier C S4: 53
Parmiani G 155
Parodi S 357
Pasquini E 771
Passalacqua R 481
Pastorino U S2: 43, S2: 125
Patel S S2: 3, S2: 81
Paull KD 755
Pavlidis NA 85, 631
Pavlovsky S 205, 533
Peaud PY 639
Pecherstorfer M 661
Pectasides D 316
Pedersen M 379
Pedersen NT 379
Pellae Cosset B S3: 43
Perales J 321
Perez EA S3: 47
Perry MC 727
Perry N 349
Pestalozzi B 445
Peters J 645
Peters K 469
Petrillo R S2: 55
Peukert M 723
Peynegre R S3: 43
Peytral C S3: 43
Pfab R S3: 33
Pfreundschuh M S4: 49, S4: 53, S4: 101
Philip T 475
Piccart MJ 141, 181, 406
Picci P 63, S2: 13, S2: 23, S2: 39

Pichert G 645
Pigna M 765
Pignatti G S2: 59
Pinedo HM 243, 755, 855
Pinto RM 145
Piva L 211
Pizzocaro G 211, 809
Plager C S2: 3
Planting ASTh 241
Ploem JS S2: 89
Plowman J 755
Pogliani EM 155
Pohl C 172, S4: 49, S4: 97
Poliwoda H 167, 487
Poppema S S4: 5
Pöttgen Ch S2: 89
Pozza F S2: 47
Price K 733
Priori T S2: 19
Pritchard KI 201
Pronzato P 165
Prosser IA 401
Putti C S2: 93

**Q**
Quagliuolo V S2: 67, S2: 125
Queirolo P 165, 559
Quoix E 813

**R**
Raats JI 409
Raña R 533
Rapoport BL 409
Raspagliesi F 117
Ratain MJ 107
Raucci U 145
Ravasi G S2: 43
Raymond AK S2: 3
Rebollo J 545
Redd WH 393
Redford J 611
Redman JR 227
Renard J 169, 399, 577
Repetto L 165, 843, S4: 69
Resta L 387
Reyner Y S2: 55
Riboli E 783
Ricard M S4: 53
Richel DJ 463, 855
Richner J 319
Rieder H 772
Rivoltini L 155
Rizzardini G 843, S4: 69
Rizzoli R 589
Robert J 651
Robillard L 401
Rodenhuis S 463, 855
Rodriguez J 711
Rodriguez M 711, S4: 87
Rodríguez-García JL 321
Roessner A S2: 33
Rohmsdahl MM S2: 3
Romaguera J 711, S4: 87
Rönnblom L 635
Roodbergen R 463
Rørth M 277, 283
Rosenberg SA 747
Rosenkaimer F 741
Rossi C S2: 97
Rossi CR S2: 111
Rosso R 165, 559
Rosso S 565
Rosti G 809
Röttgen A S4: 21
Rouëssé J S2: 75
Rowley JD 107
Rubinstein LV 59
Rudenstam C-M 733
Rüffer U S4: 101
Ruffié P 813
Ruggieri P S2: 13, S2: 39
Russell C 149
Rustin GJS 163
Rydholm A S2: 57

**S**
Sabbioni MEE 393
Sackman Muriel F 533
Sæter G S2: 7
Saijo N 273, 819
Saltiel JC 813
Saltz L 793
Salvadore M S2: 103
Salvagno L 51, 833
Salvioni R 211, 809
Sampi K 137
Sánchez Hernández JJ 861
Sandberg E 379
Sanguineti O 559
Santarelli MT 205, 533, S4: 77
Santi L S2: 119
Santoro A S2: 67, S2: 75, S2: 125, S4: 111
Sanz GF S3: 39
Sanz MA S3: 39
Sarosy G 59
Sasaki Y 273, 819
Saunders MP 574
Sause WT S3: 51
Sauter Chr 445
Sawan A 246
Scarpa A 307
Schatzmann E 825
Schellong G S4: 73
Scheulen ME 123
Schintu GM 833
Schiratti M S2: 71
Schlaerth J 149
Schmähl A 723
Schmieder A 539
Schmits R S4: 49
Schmitt G S2: 89
Schmoll H-J 167, 487, 772
Schneider G 301
Schneider M 88
Schöber Ch 167
Schobert I 172
Schöffski P 487
Scholz R S4: 49
Schornagel JH 223, 463, 549, 855
Schultz H 217
Schwartsmann G 664, 755
Schwartz L 533
Schwarze E-W S4: 31
Schwendener R 445
Schwonzen M 172
Scotlandi K S2: 29
Sculier JP 319
Secreto G 435
Seeber S 123
Segelov E 103
Seibt-Jung H S4: 105
Senent L S3: 39
Senn H-J 422, 619, 801, 825
Serra C 237
Serra M S2: 29
Serraino D 595, 843, S2: 85, S4: 69
Serrano M 321
Sertoli MR 559
Seymour J 664
Shand WS 349
Shani A 297
Shinkai T 819
Shinzato J 367
Shoemaker D 59
Siegenthaler P 169
Simmons D 239
Simoncini E 733
Skakkebæk NE 283
Skarlos D 631
Skillings J 201
Skovgaard Poulsen H 71
Slevin M 217
Smerieri F 771
Smith DB 163
Smith IE 503
Smyth JF 399, 406
Soesan M 51
Sofra M 371
Sogno G S2: 119
Solheim ØP S2: 7
Somers R S2: 75, S4: 41
Somoza N 205
Sorarù M 833
Sørensen E 379
Sorio R S2: 115
Sotti G 51
Souberbielle BE 605
Soucek M 113
Spalice A 145
Spataro V 733
Spatti G 117
Spaulding R 83
Specht L S4: 63, S4: 77
Spina M 843, S4: 69
Spinolo JA 227
Splinter TAW S3: 25
Sridhar KS 553
Stahel RA 319, 645
Stahl M 167
Stansfeld AG 349
Stein CA 571
Stein H S4: 21, S4: 27, S4: 39
Steinbrecher E S4: 27
Sternberg CN 331, 741

Steward W S2: 75
Stewart DJ 83, 201, 401
Stiefel F 422
Stoll BA 29, 435
Storelli C 387
Stoter G 102, 241, 577
Sulser H 645
Sutcliffe SB 499
Svahn-Tapper G 455
Swan F Jr 227, 711, S4: 87
Sweetenham JW 839
Szalai JP 37

**T**
Tagliabue G 233
Takagi T 137
Takahashi M 367
Talamini R 63, 625
Tamburini M 565
Taminiau AHM S2: 1
Tamura T 819
Tangco E 545
Tannock IF 83, 187
Tattersall MHN 103
Tavecchio L S2: 43
Tawadros S S4: 21
Tedesco M S2: 71
Ten Bokkel Huinink WW 406, 463, 549
Tesch H S4: 13
Tesoro-Tess JD S2: 55
Testi AM 765
Theoharis D 631
Thiébaud D 619, 661
Thiel E S4: 105
Thomas D S2: 75
Thomsen C 469
Thorling K 379
Thürlimann B 311, 619
Thyss A 88
Tienghi A S2: 19, S2: 37
Tiensuu Janson E 635
Tirelli U 595, 843, S4: 69
Toffoli G 63
Toma S 559, S2: 119
Tomiak E 181
Tommasi M 237
Tordiglione M S2: 103
Touchie M 401
Triller J 113
Trovò MG S2: 97
Trümper LH S4: 25
Trux FA 539
Tsavaris N 127
Tschiersch A S4: 49
Tubiana M S4: 129
Tumiotto L 63
Turra S S2: 111
Tursz T S2: 75
Tveter K 361

**U**
Ueda Y S2: 33
Uhrich M 571
Uys A 45

**V**
Vaccher E 843, S4: 69
Valagussa P 417, S4: 111
Valente M S2: 43
van Deijk WA 549
van der Burg MEL 241
van der Merwe R 45
van der Vegt S 549
van Eeden H 404
van Glabbeke M 577, S2: 75
van Groeningen CJ 577
van Oosterom AT 256, S2: 1, S2: 75
Van Driel-Kulker AMJ S2: 89
Vandenberg T 201
Varette C 657
Vavassori V S2: 103
Vecchiato A S2: 111
Veenhof CHN 314
Velasquez WS 227
Venner P 83
Ventafridda V 565
Venturini M 559
Venturino A S2: 119
Veraldi A S2: 93
Verma S 201, 401
Vermorken JB 97, 223
Veronesi A 237
Verweij J 223, 241, 406, 549, S2: 75
Vicini S S4: 25
Vieitez JM 545
Vigliani F S2: 111
Vignetti M 145
Vigváry Z S2: 127
Villar A 861
Vinciguerra V 727
Vinke J 475
Viñolas N 451
Visser L S4: 5
Vlasveld LT 463, 855
Voisin S 813
Vokes EE 79, 727
Volpe R S2: 51
von der Maase H 283
von Fliedner V 11
von Kalle C S4: 21
Vritsios A 553

**W**
Wagener DJTh 197, 406, S2: 75
Wagstaff J 243
Waldburger R 619
Wallace S S2: 3
Wander H 301
Wanders J 406, 463
Wandl UB 123
Wasserman JP 297
Weichselbaum RR 79
Weinberger E 571
Weinerman B 83
Weiss LM S4: 27
Weissberg D 297
Wheeler R 659
White T 455
Whitehouse JMA 839
Wildiers J 223
Wilke H 167
Willems Y 825
Williams SD 780
Wils J 197
Wiltshaw E 574
Winkelmann W S2: 33
Wolbink G-J 243
Wolf J S4: 21
Wolf M S3: 33
Woll EM 172
Woll P S2: 75
Wollmer P 455
Workman P 339, 527, 591, 699
Wrigley PFM 349
Wuisman P S2: 33
Wurm R S2: 89

**Y**
Yamakido M 819
Yamashita Y 367

**Z**
Zeuli M 741
Zorat P-L 51
Zucchi V S2: 43
Zucchinelli P S2: 125
Zunino F 117
Zupi G 741